BEAM:NSD-Beam Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 92.36

Change

0.00 (0.00)%

Market Cap

USD 6.05B

Volume

0.47M

Avg Analyst Target

USD 113.50 (+22.89%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Company Website : http://www.beamtx.com

Address : 26 Landsdowne Street, Cambridge, MA, United States, 02139

Employees : 216

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

52 Week High : 138.52

Short Ratio : 5.68

52 Week Low : 18.76

Shorted Shares : 5,337,217

200 Day Moving Average : 88.79

Shorted Shares Previous Month : 6,470,490

50 Day Moving Average : 95.74

Shares Held By Insiders : 2.03%

Short Percentage : 8.00%

Shares Held by Institutions : 83.03%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

N/A

 USD140.07B 233.80 177.21
BNTX BioNTech SE

N/A

 USD68.10B 51.40 36.74
REGN Regeneron Pharmaceuticals, Inc

N/A

 USD62.47B 16.69 13.10
VRTX Vertex Pharmaceuticals Incorpo..

N/A

 USD51.90B 19.11 12.98
ALXN Alexion Pharmaceuticals, Inc

N/A

 USD40.34B 59.23 42.56
BGNE BeiGene, Ltd

N/A

 USD29.28B N/A N/A
GMAB Genmab A/S

N/A

 USD29.00B 33.07 3.64
SGEN Seagen Inc

N/A

 USD26.42B 40.63 36.27
RPRX Royalty Pharma plc

N/A

 USD24.49B 33.25 14.58
ALNY Alnylam Pharmaceuticals, Inc

N/A

 USD21.44B N/A N/A

ETFs Containing BEAM

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.15% 66% D 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.15% 66% D 46% F
Trailing 12 Months  
Capital Gain 336.48% 98% A+ 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 336.48% 98% A+ 97% A+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 97.73% 89% B+ 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 97.73% 89% B+ 93% A
Risk Return Profile  
Volatility (Standard Deviation) 150.21% 16% F 10% F
Risk Adjusted Return 65.06% 89% B+ 80% B-
Market Capitalization 6.05B 94% A 88% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 96% A 100% A+
Price/Book Ratio 13.99 12% F 10% F
Price / Cash Flow Ratio -63.16 93% A 88% B+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -106.96% 24% F 18% F
Return on Invested Capital -73.83% 29% F 11% F
Return on Assets -37.50% 23% F 7% F
Debt to Equity Ratio 2.16% 73% C 84% B
Technical Ratios  
Short Ratio 5.68 33% F 20% F
Short Percent 14.33% 14% F 12% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector